Gene · 6147
RPL23A: ribosomal protein L23a
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL23A: ribosomal protein L23a. Genes, record 6147. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6147
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62750 | Large ribosomal subunit protein uL23 | 156 | 181 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62013 | P62750 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12287 | P62750 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12287 | P62750 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74024 | P62750 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176995 | P62750 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9754 | P62750 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2125 | P62750 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242448 | P62750 | Espacenet |
| JP 2017197443 A | 2017-11-02 | 60 | P62750 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 242448 | P62750 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants518
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL23A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 3 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| R01GM109215 | Functional Characterization of the Genetic and Environmental Determinants of Complex Traits | 2 | 2025 |
| R01HL162574 | Psychosocial and Genetic Effects on Gene Expression and Asthma | 2 | 2025 |
| K12GM068524 | San Diego IRACDA Scholars Program | 1 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 1 | 2025 |
1 to 10 of 518Source NIH's project files
See all 518 nih grantsPapers641
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study. | Medicine (Baltimore) | 2026 | 42760660 | PubTator, text mining | PubMed |
| FBXO5 regulates RPL23A to promote MDM2-mediated p53 degradation and facilitate malignant progression of breast cancer. | Breast Cancer Res | 2026 | 42343437 | PubTator, text mining | PubMed |
| xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles. | bioRxiv | 2026 | 42182318 | PubTator, text mining | PubMed |
| Diagnostic potential of circular RNAs in carotid atherosclerotic plaque vulnerability. | Noncoding RNA Res | 2026 | 41809636 | PubTator, text mining | PubMed |
| Manganese modulates hepatocellular carcinoma cytotoxicity and doxorubicin sensitivity in a dose dependent manner. | Front Oncol | 2026 | 41768239 | PubTator, text mining | PubMed |
| Organelles harbour pH gradients. | Res Sq | 2026 | 41646419 | PubTator, text mining | PubMed |
| Development of a split-toxin CRISPR screening platform to systematically identify regulators of human myoblast fusion. | Nat Commun | 2026 | 41540035 | PubTator, text mining | PubMed |
| Comprehensive whole genome sequence analysis unravels QTLs and genes under selection in Indian native riverine buffalo. | Genome | 2026 | 41539658 | PubTator, text mining | PubMed |
| Stable Cas9 expression regulates cell growth by facilitating mTORC2 activation. | Nucleic Acids Res | 2025 | 41020501 | PubTator, text mining | PubMed |
| Dual regulatory effects of gut microbiota and their metabolites in rheumatoid arthritis: balancing pathogenic and protective mechanisms. | Front Immunol | 2025 | 40370449 | PubTator, text mining | PubMed |
1 to 10 of 641
See all 641 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6147
GET https://conductscience.org/api/genes/v1/6147/patents?page=2